Temomedac Cap 20/100mg
IMPROVING PATIENT SURVIVAL RATES FOR MAELIGNANT BRAIN TUMORS STANDARD REGIMEN FOR GBM & ASTROCYTOMAS Median survival time for Anaplastic Astrocytoma patients treated with Temomedac® (chemotherapy): 13.6 months1
Temomedac Cap 20/100mg
Generic Name: Temozolomide
Indications
Newly diagnosed glioblastoma multiforme in adults:
- Used with radiotherapy, then as monotherapy.
Recurrent or progressive malignant glioma (glioblastoma multiforme or anaplastic astrocytoma) in adults and children (≥3 years):
- Used as monotherapy.
Strength
100mg Capsule
Pack Size
5 Capsules per pack
Dosage Form
Capsules
Categories
Pharmaceuticals
Therapeutic Class
Alkylating Agent